Riemser Pharma GmbH:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Riemser Pharma GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10815
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Riemser Pharma GmbH (Riemser), formerly Riemser Arzneimittel AG is a distributor of lifecycle management products. The company offers analgesics products, cardiovascular products, over-the-counter medicines, prescription drugs and dental products. It provides medical products for the treatment of infectious diseases, obesity, rheumatology, tuberculosis therapy, neurology, oncology and dermatological disorders such as psoriasis, acromycosis, acne, and herpes. Riemser also offers nutritional supplements. The company has research and development alliances with research institutes, universities, colleges and hospitals across Europe. It has operations in Germany, France and the UK. Riemser is headquartered in Greifswald, Germany.

Riemser Pharma GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Riemser Pharma GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Riemser Pharma GmbH, Medical Devices Deals, 2012 to YTD 2018 10
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Riemser Pharma Acquires European Rights to Prialt from Eisai 12
Riemser Pharma Acquires CNS Portfolio from Dolorgiet 13
RIEMSER Arzneimittel Acquires Worldwide Rights Of Ostac From Roche 14
Private Equity 15
Ardian May Sell Riemser Pharma for USD494.3 Million 15
AXA Private Equity Completes Acquisition Of Riemser Arzneimittel 17
Asset Transactions 19
Dermapharm Acquires Hyperthermic Medical Devices Business Unit from Riemser Pharma 19
Acquisition 20
Riemser Pharma to Acquire Intrapharm Labs 20
Riemser Pharma Acquires Keocyt 21
Riemser Arzneimittel To Acquire 49% Stake In anwerina 22
Riemser Pharma GmbH – Key Competitors 23
Riemser Pharma GmbH – Key Employees 24
Riemser Pharma GmbH – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Key Facts 2
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Riemser Pharma GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Riemser Pharma GmbH, Deals By Therapy Area, 2012 to YTD 2018 8
Riemser Pharma GmbH, Medical Devices Deals, 2012 to YTD 2018 10
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Riemser Pharma Acquires European Rights to Prialt from Eisai 12
Riemser Pharma Acquires CNS Portfolio from Dolorgiet 13
RIEMSER Arzneimittel Acquires Worldwide Rights Of Ostac From Roche 14
Ardian May Sell Riemser Pharma for USD494.3 Million 15
AXA Private Equity Completes Acquisition Of Riemser Arzneimittel 17
Dermapharm Acquires Hyperthermic Medical Devices Business Unit from Riemser Pharma 19
Riemser Pharma to Acquire Intrapharm Labs 20
Riemser Pharma Acquires Keocyt 21
Riemser Arzneimittel To Acquire 49% Stake In anwerina 22
Riemser Pharma GmbH, Key Competitors 23
Riemser Pharma GmbH, Key Employees 24
Riemser Pharma GmbH, Other Locations 25
Riemser Pharma GmbH, Subsidiaries 25

List of Figures
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Riemser Pharma GmbH, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Riemser Pharma GmbH:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bellway Plc (BWY):企業の財務・戦略的SWOT分析
    Bellway Plc (BWY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Kosmos Energy Ltd (KOS):石油・ガス:M&Aディール及び事業提携情報
    Summary Kosmos Energy Ltd. (Kosmos) is an independent oil and gas exploration and production company. Its primary areas of operation are frontier and emerging areas along the Atlantic Margin. The company’s asset portfolio includes existing production and development projects offshore Ghana, discover …
  • Janus Henderson Group Plc:企業の戦略・SWOT・財務情報
    Janus Henderson Group Plc - Strategy, SWOT and Corporate Finance Report Summary Janus Henderson Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Nakheel:企業の戦略・SWOT・財務分析
    Nakheel - Strategy, SWOT and Corporate Finance Report Summary Nakheel - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Eli Lilly and Co (LLY):医療機器:M&Aディール及び事業提携情報
    Summary Eli Lilly and Co (Lilly) is a healthcare company that discovers, develops and markets human and animal healthcare products. The company offers medicines for cardiovascular conditions, diabetes, cancer, neurological problems, immune disorders, men's health and musculoskeletal problems. It als …
  • Grupa Azoty SA (ATT):企業の財務・戦略的SWOT分析
    Grupa Azoty SA (ATT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Select Energy Services Inc (WTTR):企業の財務・戦略的SWOT分析
    Select Energy Services Inc (WTTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Petronas Dagangan Berhad (PETDAG):企業の財務・戦略的SWOT分析
    Petronas Dagangan Berhad (PETDAG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Origin Energy Ltd (ORG):企業の財務・戦略的SWOT分析
    Origin Energy Ltd (ORG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Zayo Group Holdings Inc (ZAYO):企業の財務・戦略的SWOT分析
    Zayo Group Holdings Inc (ZAYO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • RHI Magnesita N.V.:企業の戦略・SWOT・財務情報
    RHI Magnesita N.V. - Strategy, SWOT and Corporate Finance Report Summary RHI Magnesita N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Spritzer Bhd:企業の戦略・SWOT・財務情報
    Spritzer Bhd - Strategy, SWOT and Corporate Finance Report Summary Spritzer Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Vivendi S.A. (VIV):企業の財務・戦略的SWOT分析
    Vivendi S.A. (VIV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Enanta Pharmaceuticals Inc (ENTA):企業の財務・戦略的SWOT分析
    Summary Enanta Pharmaceuticals Inc (Enanta) is a biotechnology company. It discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s lead product candidate includes EDP-305, a farnesoid X receptor (FXR) agonist intended for the treatment of n …
  • Husky Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Husky Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Husky Energy Inc (Husky) is an integrated energy company. It operates across the oil and gas value chain. Its upstream operations include the exploration, development and production of crude oil, bi …
  • BKW AG:企業の戦略・SWOT・財務情報
    BKW AG - Strategy, SWOT and Corporate Finance Report Summary BKW AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • University of Pennsylvania:企業のM&A・事業提携・投資動向
    University of Pennsylvania - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's University of Pennsylvania Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Ca Immobilien Anlagen Ag:企業の戦略・SWOT・財務分析
    Ca Immobilien Anlagen Ag - Strategy, SWOT and Corporate Finance Report Summary Ca Immobilien Anlagen Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • United Therapeutics Corp (UTHR):企業の製品パイプライン分析
    Summary United Therapeutics Corp (United Therapeutics) develops and commercializes innovative pharmaceutical products for the treatment of cardiovascular disorders, particularly pulmonary arterial hypertension and infectious diseases. The company's products consist of prostacyclin analogues includin …
  • Bucher Industries AG:企業の戦略・SWOT・財務情報
    Bucher Industries AG - Strategy, SWOT and Corporate Finance Report Summary Bucher Industries AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆